For patients with coronary artery disease (CAD), intensive reduction of low-density lipoprotein cholesterol (LDL-C) levels via 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase inhibitor (statin) therapy is recommended [1, 2]. Here, HMGCR is linked to coronary artery disorder.